Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QIV-HD Immunogenicity and Safety in Adults 60+
NCT04024228Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2019
- Primary completion
- Jan 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 6
01
Overview
A Phase 3 trial of Efluelda in influenza, sponsored by Sanofi. Started Oct 2019; status: completed.
02
Drugs
Efluelda
03
Conditions
influenza
Beyond the preview
Go deeper on NCT04024228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04024228.